Kivu Biosciences, a San Francisco, CA-based biotech company developing antibody-drug conjugates, raised $92M in Series a funding.
The round was led by Novo Holdings, with participation from Gimv, Red Tree Venture Capital, HealthCap as well as existing investors BioGeneration Ventures, M Ventures, and Brabantse Ontwikkelings Maatschappij (BOM).
The company intends to use the funds for the clinical development of multiple ADC programs.
Led by President and COO Mohit Trikha, Kivu Bioscience is advancing next-generation antibody-drug conjugates (ADCs) in oncology. The company’s proprietary linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing its first two lead candidates to clinical trials expected to begin in 2025.
